• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Orix Corporation ADR

Orix Corporation ADR

ORIX Corp ADR IX

Last Price$74.16Day Change (%)-0.31%
Open Price$73.71Day Change ($)-0.23
Day Range73.49–74.3552-Week Range57.00–77.92

As of Fri 9/30/2016 5:27:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Senator Pete Domenici Announces Solution for Oklahoma Earthquakes is in IX Power’s Produced Water Treatment from Los Alamos

    Senator Pete Domenici Announces Solution for Oklahoma Earthquakes is in IX Power’s Produced Water Treatment from Los Alamos

  2. Fitch Rates Jamestown CLO IX Ltd./Corp.

    Fitch Rates Jamestown CLO IX Ltd./Corp.

  3. Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis

    Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis

  4. Acadia Realty Trust to Present at the Bank of America Merrill Lynch 2016 Global Real Estate Conference

    Acadia Realty Trust to Present at the Bank of America Merrill Lynch 2016 Global Real Estate Conference

  5. Algonquin Power & Utilities Corp. and The Empire District Electric Company Announce Missouri Public Service Commission Authorization of Merger Transaction; Motion to Amend Kansas Procedural Schedule

    Algonquin Power & Utilities Corp. and The Empire District Electric Company Announce Missouri Public Service Commission Authorization of Merger Transaction; Motion to Amend Kansas Procedural Schedule

  6. Westlake Chemical Announces Expiration and Final Results of the Exchange Offers and Consent Solicitations for Certain Axiall Notes

    Westlake Chemical Announces Expiration and Final Results of the Exchange Offers and Consent Solicitations for Certain Axiall Notes

  7. LifePoint Health Appoints Michael S. Coggin as Chief Financial Officer

    LifePoint Health Appoints Michael S. Coggin as Chief Financial Officer

  8. Moats and Growth Drivers Look Solid for Post-Split Baxter

    Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

  9. Novo's Scale Advantages and Drug Lineup Broaden Its Wide Moat

    Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.